文献速递神经肿瘤小儿神经外科与脑积水

脑室内B7-H3 CAR-T治疗非脑桥DMG及复发/难治儿童中枢神经系统肿瘤的1期试验

Intracerebroventricular B7-H3-targeting CAR T cells for non-pontine DMG and recurrent/refractory pediatric CNS tumors: a phase 1 trial.
PubMed 文献 · Neuro Oncol · 2026-07-25

BrainChild-03(NCT04185038)是一项单中心、剂量递增1期研究,评估重复脑室内输注B7-H3 CAR-T细胞在复发/难治儿童中枢神经系统肿瘤(B组)中的可行性、安全性和耐受性。36例入组患者中35例成功制备,26例接受治疗;剂量从1×10^7递增至10×10^7 CAR-T细胞/剂,未观察到剂量限制性毒性,最常见不良事件为头痛、发热和恶心;中位生存期自首次输注起为11.5个月,2例达部分缓解。结论认为重复脑室内B7-H3 CAR-T细胞给药在多种儿童中枢神经系统肿瘤中可行且可耐受,支持未来进一步研究。

要点

  • 重复脑室内B7-H3 CAR-T细胞给药在儿童中枢神经系统肿瘤中可行且可耐受。
  • 剂量递增至10×10^7 CAR-T细胞/剂未观察到剂量限制性毒性。
  • 中位生存期自首次输注起为11.5个月,2例患者达部分缓解。

核心结论

  • 重复脑室内B7-H3 CAR-T细胞给药在多种儿童中枢神经系统肿瘤中可行且可耐受,支持未来试验继续研究。

研究设计与样本

  • BrainChild-03(NCT04185038)为单中心、剂量递增1期研究,B组纳入复发/难治中枢神经系统肿瘤或进展前/后非脑桥弥漫性中线胶质瘤患者,接受重复脑室内B7-H3 CAR-T细胞输注。
  • 36例入组患者中35例成功制备,26例接受治疗;中位年龄10岁(范围1-26岁)。

主要发现

  • 剂量从1×10^7递增至10×10^7 CAR-T细胞/剂,该剂量确定为最大耐受剂量方案,未观察到剂量限制性毒性。
  • 共181次输注(中位7次/患者),常见不良事件包括头痛(n=26)、发热(n=15)和恶心(n=14)。
  • 自首次输注起中位生存期为11.5个月,范围从3.2个月(松果体母细胞瘤、高级别胶质瘤)到21.4个月(室管膜瘤);2例患者达部分缓解。

关键数值与推荐

  • 最大耐受剂量方案为10×10^7 CAR-T细胞/剂,未观察到剂量限制性毒性。

临床怎么用

  • 对于标准治疗失败的复发/难治儿童中枢神经系统肿瘤,重复脑室内B7-H3 CAR-T细胞给药是可行且可耐受的选择,但疗效仍需进一步试验确认。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: High-grade central nervous system (CNS) tumors carry a poor prognosis with limited curative options if first-line therapy fails. B7-H3 is expressed in many of these tumors, and chimeric antigen receptor (CAR) T cell therapy is an emerging immunotherapeutic strategy. METHODS: BrainChild-03 (NCT04185038) is a single-center, dose-escalation phase 1 study of repeated intracerebroventricular (ICV) B7-H3 CAR T cells in children and young adults with recurrent/refractory CNS tumors (Arms A, B) and diffuse intrinsic pontine glioma (DIPG, Arm C). Here, we report results from Arm B, in which patients with refractory/relapsed CNS tumors or pre- or post-progression non-pontine diffuse midline glioma (DMG) received repeated ICV infusions. Primary objectives were feasibility and safety/tolerability; secondary objectives included CAR T cell detection, disease response, and survival. RESULTS: Of 36 enrolled patients (atypical teratoid rhabdoid tumor n = 5, DMG n = 8, embryonal tumor with multilayer rosettes n = 2, ependymoma n = 4, high-grade glioma n = 6, medulloblastoma n = 8, pineoblastoma n = 3), manufacturing was successful for 35 patients, 26 of whom received therapy. Median age was 10 years (range 1-26). Dose escalation from 1 × 107 to 10 × 107 CAR T cells/dose identified this dose as the maximally tolerated dose regimen, with no dose-limiting toxicities observed. Across 181 total doses (median 7/patient), common adverse events included headache (n = 26), fever (n = 15), and nausea (n = 14). Median survival from first infusion was 11.5 months, ranging from 3.2 months (pineoblastoma, HGG) to 21.4 months (ependymoma); two patients achieved a partial response. CONCLUSIONS: Repeated ICV B7-H3 CAR T cell dosing is feasible and tolerable across a spectrum of pediatric CNS tumors, supporting continued investigation in future trials. Children with aggressive brain and spinal cord tumors have few treatment options when standard therapy no longer works. This study tested a new immunotherapy called B7-H3 CAR T cell therapy, which uses a patient's own immune cells to recognize and attack cancer cells. Twenty-six children and young adults received repeated CAR T cell infusions directly into the fluid surrounding the brain. The treatment was successfully manufactured for nearly all patients and was generally well tolerated, with headaches, fever, and nausea being the most common side effects. Two patients experienced meaningful tumor shrinkage, and some patients lived longer than expected. These early results show that this approach is safe and feasible and support further studies to determine how well it can improve outcomes for children with these difficult-to-treat tumors.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Ronsley R, Huang W, Rohlf E, et al. Intracerebroventricular B7-H3-targeting CAR T cells for non-pontine DMG and recurrent/refractory pediatric CNS tumors: a phase 1 trial. Neuro Oncol. 2026. PMID: 42503899. doi:10.1093/neuonc/noag171

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。